<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726920</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-NRP-03(04/12)</org_study_id>
    <nct_id>NCT01726920</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.</brief_title>
  <acronym>Copérnico</acronym>
  <official_title>A Phase III, Multicenter, National, Open, Randomized, Parallel and Comparative Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg for the Acute Treatment of Migraine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5
      mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment
      of migraine.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to budget limitations, the company decided to withdraw this study.
  </why_stopped>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache relief 2 hours after dosing, without use of rescue medication</measure>
    <time_frame>2 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0= none, 1= mild, 2= moderate, and 3= severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache relief 4 hours after dosing, without use of rescue medication</measure>
    <time_frame>4 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0= none, 1= mild, 2= moderate, and 3= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication</measure>
    <time_frame>2 to 24 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-free response 2 and 4 hours after dosing, without use of rescue medication</measure>
    <time_frame>2 and 4 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0= none, 1= mild, 2= moderate, and 3= severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of pain-free response between 2 and 24 hours, without use of rescue medication</measure>
    <time_frame>2 to 24 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0= none, 1= mild, 2= moderate, and 3= severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from nausea, vomiting, photophobia and phonophobia 2 and 4 hours after dosing</measure>
    <time_frame>2 and 4 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for the presence of vomiting, nausea, photophobia and phonophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of freedom from nausea, vomiting, photophobia and phonophobia between 2 and 24 hours after dosing, without use of rescue medication</measure>
    <time_frame>2 to 24 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for the presence of vomiting, nausea, photophobia and phonophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of pain between 2 and 24 hours after dosing, without use of rescue medication</measure>
    <time_frame>2 to 24 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0= none, 1= mild, 2= moderate, and 3= severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once</measure>
    <time_frame>2 to 24 hours after single dose treatment</time_frame>
    <description>Participants were evaluated (self-assessment) about use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.</measure>
    <time_frame>Collection of safety data throughout the whole study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Migraine</condition>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>naratriptan + naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination of naratriptan + naproxen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naratriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naratriptan + naproxen</intervention_name>
    <description>Tablets containing naratriptan 2,5 mg + naproxen 500 mg</description>
    <arm_group_label>naratriptan + naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naratriptan</intervention_name>
    <description>Tablets containing naratriptan 2,5 mg</description>
    <arm_group_label>naratriptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>Tablets containing naproxen 500 mg</description>
    <arm_group_label>naproxen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient, age in the range of 18-65 years inclusive that has onset of
             migraine before age 50;

          -  Patient has at least a 3-month history of migraine with or without aura according to
             the ICHD-II, 2004, IHS (International Headache Society) criteria;

          -  Patients experienced an average migraine headache frequency of 2-6 moderate or severe
             attacks per month in the last 03 months prior to screening visit;

          -  Patients able to distinguish his/her migraine attacks from any other types of
             headaches;

          -  Patients able to understand and consent to participate in this clinical study,
             expressed by signing the Informed Consent (IC).

        Exclusion Criteria:

          -  History of more than 6 migraine attacks/month in the last 03 months prior to screening
             visit;

          -  History of non-migraine headache frequency ≥ 15 days/month in each of the 3 months
             prior to screening;

          -  History of following migraine variants, according to the ICHD-II, 2004, IHS
             (International Headache Society): basilar migraine, aura without headache, familial
             hemiplegic migraine, sporadic hemiplegic migraine or aura with non-migraine headache;

          -  If female of childbearing potential, has a negative urine pregnancy test at Visit 0
             and doesn't use, or doesn't agree to use, for the duration of the study, a medically
             acceptable form of contraception as determined by the investigator;

          -  Woman in pregnancy or lactation period;

          -  History of epilepsy or psychiatric condition that may affect the compliance of the
             treatment;

          -  Patients in acupuncture treatment for the symptoms of migraine attacks;

          -  History or symptoms of cardiovascular disease (myocardial infarction, ischemic heart
             disease, or with Prinzmetal's angina) or has symptoms of ischemic heart disease;

          -  Suffers from peripheral vascular disease;

          -  History of cerebrovascular pathology including stroke and/or transient ischemic
             attacks;

          -  History of allergic reactions to naproxen preparations, including subjects in whom
             aspirin or other NSAID drugs induce the syndrome of asthma, rhinitis, nasal polyps or
             urticaria;

          -  Diagnosis of renal or hepatic failure;

          -  Has significant (as determined by the investigator) cardiovascular risk factors that
             may include uncontrolled high blood pressure, post-menopausal women, males over 40
             years old, hypercholesterolemia, obesity, diabetes mellitus, smoking, or a family
             history of cardiovascular disease in a 1st degree relative;

          -  Patients who have stopped or changed the dosage of the preventive treatment of
             migraine in the last 2 weeks prior the screening visit (V0), including the use of
             calcium channel blockers, tricyclic antidepressants, beta blockers or serotonergic
             medications for any other indications;

          -  Use of prohibited medicine as shown in 9.3 item of this protocol;

          -  Inability to understand and report the categorical scale debilitating functional of
             study or symptoms diary;

          -  Has abused, in the opinion of the Investigator, any of the following drugs, currently
             or within the past 2 years: opioids, alcohol, barbiturates, benzodiazepine, cocaine or
             abuse of drugs for migraine treatment including narcotics or ergotamines headache in
             the past 03 months;

          -  Hypersensitivity to naratriptan, naproxen, or any of its components;

          -  Hypersensitivity to sulfonamides;

          -  History of malignancy ≤ 5 years or &gt; 5 years without documentation of remission /
             cure, for example, melanoma, leukemia, lymphoma, myeloproliferative disorders and
             renal cell carcinoma of any duration. Exception: Subjects with basal cell skin
             cancers, squamous cell, and cervical cancer in situ may be eligible;

          -  Participation in last one year of clinical protocols, unless it can be direct benefit
             to patient;

          -  Any finding of clinical observation (anamnesis and physical exam) laboratory
             abnormality (eg, blood glucose, blood count), disease (for example, liver,
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may
             endanger the patient or interfere with the endpoints of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2012</study_first_submitted>
  <study_first_submitted_qc>November 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Naratriptan</keyword>
  <keyword>Naproxen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Naratriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

